Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotech shares slide after glimpse of trial data on cancer drug | Financial Times
PumaBiotech (@pumabiotech) / Twitter
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotechnology
Why Puma Biotechnology Shares Dropped 17.7% This Week | The Motley Fool
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection
Puma Biotechnology
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
Puma Biotechnology
Puma Biotechnology
Puma Biotech plunges on drug side effects
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
SEC charges former Puma biotech exec with $1.1 million in insider trading
PumaBiotech (@pumabiotech) / Twitter
Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles Business Journal
